Phenacetin was used as an analgesic and fever-reducing drug in both human and veterinary medicine for many years. It was introduced into therapy in 1887 and was extensively used in analgesic mixtures until it was implicated in kidney disease (nephropathy). Chemically N-(4-ethoxyphenyl)acetamide, formula C10H13NO2, molar mass 179.22 g mol-1, phenacetin is a white crystalline powder with a melting point around 134 to 136 degrees C, low aqueous solubility and good solubility in organic solvents such as ethanol and chloroform. Its clinical effect arises largely from hepatic O-deethylation to paracetamol, which provides central analgesic and antipyretic activity, while parent compound and other metabolites have been associated with renal toxicity and carcinogenic risk. Phenacetin was manufactured historically by acetylation of p-phenetidine; analysis required chromatographic purity checks, stability profiling under heat and light, and identification of aromatic amine impurities.
Typical impurity and related compound profiles reflect the synthetic route and storage history. Major related substances include p-phenetidine (4-ethoxyaniline) formed as an unreacted precursor or by hydrolytic deacetylation, acetanilide from incomplete ethoxylation or side reactions, and paracetamol as a metabolic or oxidative product. In crude or industrial material p-phenetidine can be the principal impurity and is commonly observed from trace levels up to several tenths of a percent; after purification high quality material is expected to be greater than 98 to 99 percent pure with major impurities at low ppm to about 0.1 percent range. Acetanilide and other aniline derivatives are usually present at lower levels typically below 0.05 to 0.2 percent. Residual solvents and trace oxidation products may be present within standard ICH limits for solvents and specified degradation products. Quantitative limits historically applied in analytical work varied by source, but safe handling and removal of aromatic amines is critical because of their toxicological profiles.
Phenacetin was used historically as an analgesic and antipyretic, relieving pain and reducing fever; its clinical activity is largely due to hepatic conversion to paracetamol. It is no longer considered a safe choice because of its association with renal injury and other toxicities.
Phenacetin has been banned in India for the same public health reasons that led to restrictions elsewhere: a well documented association with analgesic nephropathy, renal papillary damage, and evidence linking long term use to increased cancer risk. Regulatory action removed it from therapeutic use to protect public health.
No. Phenacetin and paracetamol are different chemical entities. Phenacetin is metabolized in the liver to paracetamol, which provides much of the analgesic effect, but the two compounds differ in structure, metabolism, toxicology, and regulatory status; paracetamol remains widely used while phenacetin has been withdrawn in many jurisdictions.
Phenacetin is not used in modern approved therapeutics in most countries and is banned or withdrawn in many markets due to safety concerns. It may still be encountered in historical reference, analytical laboratories, or illicit contexts, but it is not part of current standard medical practice.
